Vinflunine

Vinflunine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Vinflunine is a chemotherapeutic agent used in the treatment of various types of cancer. It is a vinca alkaloid derivative, specifically designed to improve upon the efficacy and safety profile of its predecessors, such as vincristine and vinblastine.

Mechanism of Action

Vinflunine works by inhibiting microtubule assembly, which is crucial for cell division. By disrupting the microtubule dynamics, vinflunine effectively halts the mitotic process, leading to apoptosis of the cancer cells. This mechanism is similar to other vinca alkaloids, but vinflunine has been modified to enhance its binding affinity and reduce neurotoxicity.

Clinical Use

Vinflunine is primarily used in the treatment of urothelial carcinoma, particularly in patients who have previously been treated with platinum-based chemotherapy. It has also been investigated for use in other types of cancer, including non-small cell lung cancer and breast cancer.

Side Effects

Common side effects of vinflunine include neutropenia, anemia, constipation, and fatigue. Less common but serious side effects can include cardiotoxicity and neurotoxicity. Patients undergoing treatment with vinflunine require regular monitoring of their blood cell counts and organ function.

Pharmacokinetics

Vinflunine is administered intravenously and has a complex pharmacokinetic profile. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system. The drug and its metabolites are excreted mainly through the biliary route.

Development and Approval

Vinflunine was developed by Pierre Fabre Laboratories and received approval for use in the European Union in 2009. It is not approved by the Food and Drug Administration (FDA) for use in the United States.

Related pages

• Vinca alkaloid
• Chemotherapy
• Cancer treatment

• 
  Vinflunine